The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Wegovy will now be the GLP-1 weight loss drug of choice under plans that are managed by CVS Caremark. If they stay on Zepbound for their GLP-1 weight loss treatment, they will have to pay full ...

Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...

Zepbound beats Wegovy for weight loss in first head-to-head trial of GLP-1 drugs The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than ...

The main result – reported earlier – was an overall weight reduction of 20.2% with Zepbound at 72 weeks, compared to 13.7% with Wegovy.

But Lilly's (LLY.N) Zepbound therapy outstripped Wegovy in weekly new prescriptions this year and the company struggles to convince investors it can remain competitive in the weight-loss boom.

In the third quarter, Novo Nordisk reported Wegovy sales grew 79% to almost $2.5 billion, while Lilly booked $1.26 billion from Zepbound, around $500 million lower than analyst forecasts.